Connect with us

Hi, what are you looking for?

Jewish Business News


Teva reports success in for Moderate to Severe Chronic Low Back Pain Treatment study

The Phase III trial results showed significant improvement in the treatment of chronic low back pain.


Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced success in a Phase III clinical trial for its abuse-deterrent extended-release CEP-33237 drug for chronic low back pain.

The results showed significant improvement in the treatment of patients’ chronic low back pain as measured by both weekly average Worst Pain Intensity and weekly Average Pain Intensity scores. CEP-33237 is a hydrocodone bitartrate acetaminophen-free formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The drug had a safety profile consistent with the known safety profile of hydrocodone and other opioid analgesic therapies.

“With more than 100 million Americans living with the distress of chronic pain, patients, clinicians and society as a whole have a real need for effective opioid therapies, ” said Teva Global R&D president and Chief Scientific Officer Dr. Michael Hayden.

Teva plans to submit a New Drug Application (NDA) for CEP-33237 to the US Food and Drug Administration (FDA) by the end of 2014.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.